Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.54 |
| ▸ | PYGL | P06737 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107346 | 1.00 | PABPC1 (0.63) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL2107052 | 1.00 | PABPC1 (0.63) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL2106973 | 0.94 | PABPC1 (0.59) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL2106972 | 0.94 | PABPC1 (0.59) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL28760270 | 0.94 | PABPC1 (0.59) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL6163240 | 0.90 | KMT2A (0.59) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL6163231 | 0.90 | KMT2A (0.59) | PABPC1KMT2ACTSSCTSKMAPK1 | |
| SCHEMBL6162295 | 0.89 | KMT2A (0.58) | PABPC1KMT2AMAPK1CYP51A1PYGL | |
| SCHEMBL6162303 | 0.89 | KMT2A (0.58) | PABPC1KMT2AMAPK1CYP51A1PYGL | |
| SCHEMBL6162815 | 0.89 | KMT2A (0.71) | PABPC1KMT2ACTSSCTSKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | PABPC1 1305/4885KMT2A 2476/4885CTSS 2832/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | PABPC1 1305/4885KMT2A 2476/4885CTSS 2832/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | PABPC1 1305/4885KMT2A 2476/4885CTSS 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.